RBQM Ops 2022 - Day 2 Panel session
Panel Session Day 2 RBQM Ops 2022
data, qm, rbqm, site, people, technology, study, organisation, monitoring, phase, presentations, piece, industry, sponsors, central, patient, important, bit, early, clinical research
Duncan Hall, Nicole Stansbury, Lisa Freeman, Rosie McKellar, Kirsten McAulay
Okay, well, we're just about on the hour now. So, we've got lots of people coming into the session to join us. So, I just wanted to start off by, first of all thanking all of the panelists for today, Nicole, Rosie, Lisa, and Kirsten, all of you today did presentations. So, thank you for that as well. Presentations have been absolutely fantastic. And, again, really appreciate everyone's time in preparing the presentations and delivering those today. Really looking forward to, to the to the panel discussion today.
We had a really lively session. Yes, last night at the same time. Interestingly, the way things have worked out with our panelists as yesterday was quite Sponsor driven. So, most of the panelists were from sponsors, we did have one tech vendor as well, today, we've got a much stronger CRO background. So, it'll be interesting to see whether that that changes, viewpoints and opinions, but So again, just for the audience, everyone that's listening in just wanted everybody to know that the team today that are on our panel are primarily from CRO backgrounds, you've obviously seen the introductions for those that have seen their sessions, so you know, where they're where their backgrounds are from.
It's been really, again, a slightly different set of presentations today really getting down into some of the operational detail. And the I think, Elaine from worldwide did a did a great job of bringing some of the sort of human factors into RBQM. And now I think bolstered Lisa, with your presentation on the organisation and the org structures and the sort of employee sort of rewards and retention was really fantastic. I think one of the other things that I really liked, just that came up today around technology was just that the importance of being able to fine tune the technology to the needs of a particular study and being able to pull out specific critical endpoints and that without those endpoints, RBQM very quickly becomes quite generic and sort of suddenly loses its value.
So, we've got, I mean, and obviously, it's hard to say we've talked about talk about years of experience is a little bit rude in front of a roomful of ladies, but we have got a lot of experience in the room. So, I'm really looking forward to, to the feedback on some of the questions I've got today. I wanted to start right back at the beginning of the day today, where we're starting to talk about phase one, trials and the applicability of RBQM to phase one.
One of the things that I had always thought would be more apparent with RBQM was using the outputs of phase one to inform phase two and onward. And that's not something that I've seen a lot of it didn't really come out in today's presentations at all. But with the experience that we've got in the room today there has anybody actually done that has anyone sort of really flowed through from phase one into phase two and actually used, perhaps the findings, the thresholds, the signals, the site performance, or the site quality risk areas in order to help sort of set up for later phase studies.
To see the full content, please click on the button below.